UK and US Strike Zero Tariff Agreement on Pharmaceuticals

The United Kingdom and the United States have finalized an agreement ensuring that pharmaceutical imports from the UK will face no tariffs when entering the US market.

As part of this arrangement, the UK will increase the cost it bears for medicines procured through the National Health Service (NHS), while securing a commitment from the US that import duties on UK-manufactured pharmaceuticals will remain at zero for a period of three years.

This marks a significant shift, as it is the first instance in over two decades where the NHS is set to raise its expenditure on medications.

The deal emerges in the wake of threats from US President Donald Trump, who had suggested imposing tariffs up to 100% on branded drug imports, a critical export sector for the UK.

Peter Kyle, Secretary of State for Business and Trade, emphasized the importance of this agreement, stating that it guarantees tariff-free access for UK pharmaceutical exports—valued at a minimum of £5 billion annually—thereby safeguarding jobs, encouraging investment, and positioning the UK as a key player in global life sciences.

Recent statistics reveal that the UK exported £11.1 billion worth of medicines to the US in the year leading up to September, constituting 17.4% of all UK goods exports during that timeframe, according to the Department for Business and Trade.

Earlier this year, pharmaceuticals were exempt from a wave of tariffs announced by Trump. However, he has consistently warned of potential tariff increases on medications, citing concerns over America’s dependency on foreign-produced drugs and advocating for a boost in domestic manufacturing.

Trump has also argued that American consumers essentially subsidize the cost of medications for other developed nations due to high prices, urging that other countries should contribute more financially.

Under the newly established terms, the UK will raise the price threshold at which it considers new treatments excessively costly by 25%. Additionally, the overall NHS budget for medications is projected to rise, targeting an increase from 0.3% to 0.6% of GDP within the next decade.

Furthermore, the repayment obligations of drug manufacturers to the NHS, aimed at preventing overspending, will be capped at 15%, a decrease from over 20% in the previous year.

In return, UK pharmaceutical exports will be shielded from any tariff hikes for the next three years.

Kush Desai, a spokesperson for the White House, characterized the arrangement with the UK as a landmark move towards ensuring that other developed nations contribute equitably.

This agreement intensifies an ongoing debate in the UK regarding the relationship between the government and the pharmaceutical sector concerning drug approvals and the financial burden of medications on the NHS.

In August, Health Secretary Wes Streeting expressed his determination to prevent drug companies from overcharging the UK after negotiations with pharmaceutical representatives regarding drug prices stalled.

Conversely, Science Minister Sir Patrick Vallance acknowledged the necessity for the NHS to allocate greater funding for medications, recognizing a decline in the proportion of its budget dedicated to pharmaceuticals over the past ten years.

The NHS’s advisory body, NICE, has projected that these adjustments may lead to the approval of an additional three to five new medications annually, with the current assessment rate being around 70 drugs per year, of which 90% receive approval.

The financial implications for the NHS remain uncertain, with medications currently comprising approximately 10% of its budget. However, Sally Gainsbury from the Nuffield Trust think tank warned that this agreement could result in an extra £3 billion in drug spending, which is concerning given the current budget constraints.

Gainsbury stated, “The additional costs must be fully funded by the Treasury,” suggesting that investing in areas such as general practitioner services or addressing hospital backlogs might be more beneficial than expanding drug budgets.

In outlining the new agreement, the UK government highlighted that it stands as the only nation globally to secure a zero percent tariff rate on pharmaceutical imports.

European officials previously indicated their belief that their pharmaceutical exports would be safeguarded under agreements made over the summer, which set tariffs on most goods at 15%.

The agreement comes in response to mounting pressure on the UK government following the cancellation or delay of numerous significant pharmaceutical investments in the country over the past 18 months, as companies redirect their focus to the US.

In mid-September, British pharmaceutical leader GSK committed to a $30 billion (£22 billion) investment in research and manufacturing within the US over the next five years.

Just a week prior to GSK’s announcement, US pharmaceutical firm Merck, known as MSD in Europe, disclosed that it would be abandoning its planned £1 billion expansion of its UK operations.

Shortly thereafter, AstraZeneca also revealed it was putting a hold on a proposed £200 million investment in a research facility in Cambridge, while previously announcing a $50 billion investment in drug manufacturing and R&D in the US.

William Bain, head of trade policy at the British Chambers of Commerce, expressed satisfaction at the delivery of the promised protections from US tariffs by UK officials earlier this year.

Bain remarked, “This deal is a significant win. It will foster exports, encourage investment, and enhance the UK’s standing as a competitive base for the production and innovation of leading medications and treatments.”

Bristol Myers Squibb, a US pharmaceutical company, indicated that it now anticipates investing over $500 million in the UK over the next five years in areas such as research, development, and manufacturing.

Chris Boerner, the chief executive, stated, “This agreement signifies progress and creates a favorable environment for our continued operations in the UK.”

In April, the White House initiated a formal investigation into the implications of pharmaceutical imports on national security, marking the initial steps towards potential tariffs.

In a post on Truth Social in September, Trump threatened to escalate tariffs on branded drugs—a specific category of medications imported by the US—up to 100%, although the White House did not implement this plan, citing ongoing negotiations with manufacturers.

Upon announcing the agreement on Monday, US Health Secretary Robert Kennedy Jr. asserted that Americans “should not bear the highest drug costs globally for medications they have financially supported.”

He added, “This agreement with the United Kingdom strengthens the global landscape for innovative medicines and restores overdue balance to US-UK pharmaceutical trade.”